equityflowunderstand the flow and follow it
EquityFlow › Companies › ARTBIO

ARTBIO

Biotech · Oslo, NO

Alpha radioligand therapies using lead-212 for cancer (lead candidate AB001)

Funding history

DateRoundAmount
Jun 2023Seed
Oslo-based ARTBIO raised a 23M USD seed led by F-Prime Capital and Omega Funds to develop its lead-212 radiopharmaceuticals for prostate cancer.
$23M

Investors

Tap an investor to see what else they have backed.

F-Prime CapitalOmega Funds

Other companies in Biotech

ImperagenHaga BiosciencePixelgen TechnologiesGallantChai DiscoverySNIPR BiomeCellbox LabsScope BiosciencesGenLuminaActitheraNUCLIDIUMAnocca

Other companies in NO

CloudgeniONiOActitheraSaga RoboticsTwoRemora RoboticsJournaliaKongsberg FerrotechCorvus EnergySensor GlobeWeWillWriteSonair

Other companies at Seed stage

&Open(Re)vive1-2-Taste100% Livre1000 Satellites100ms10club10pct.10x Science10x.team123Projetei150 Minuten
Explore funding flow on EquityFlow →

Data is community-curated and may be incomplete.